Hospital
Pih Health Good Samaritan Hospital
Pih Health Good Samaritan Hospital was paid $19.10M by Medicaid between Jan 2018 and Nov 2024, across 263 billing codes. Its largest line is 0450, Emergency room services — 18% of everything it billed.
33Billing provider infoPIH HEALTH GOOD SAMARITAN HOSPITAL
LOS ANGELES, CA 90017
LOS ANGELES, CA 90017
33aNPI1508859323assigned 08/26/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.10M
24GClaims819,097
24DCodes billed263
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#128 of 410
Median peer was paid$6.90M
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 113,797 | $2.85M | |
| 2019 | 96,613 | $2.67M | |
| 2020 | 82,953 | $2.20M | |
| 2021 | 96,927 | $2.29M | |
| 2022 | 119,767 | $2.62M | |
| 2023 | 145,978 | $3.17M | |
| 2024incomplete | 163,062 | $3.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 18% | 78,679 | 64,696 | $3.38M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.8% | 6,967 | 6,143 | $1.11M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.8% | 8,724 | 7,872 | $916K |
| Z7502 | 3.7% | 18,538 | 18,331 | $699K | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.6% | 5,174 | 4,885 | $690K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.6% | 33,031 | 27,439 | $686K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.2% | 17,909 | 15,788 | $620K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 2,035 | 1,903 | $526K |
| J3490 | Unclassified drugs | 2.5% | 42,559 | 24,889 | $478K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.3% | 3,705 | 3,470 | $437K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 53,399 | 46,077 | $366K |
| 0360 | 1.9% | 1,676 | 1,436 | $365K |
251 more codes
| 0250 | 1.8% | 12,182 | $352K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.8% | 8,681 | $343K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 13,194 | $332K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 27,552 | $312K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.6% | 12,789 | $310K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 24,487 | $302K |
| 0270 | 1.5% | 13,866 | $288K | |
| 80053 | Comprehensive metabolic panel | 1.5% | 22,829 | $282K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 8,580 | $270K |
| 84484 | 1.3% | 20,465 | $242K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 11,509 | $232K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 4,594 | $227K |
| 99199 | Unlisted special service, procedure or report | <1% | 4,464 | $187K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,433 | $182K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,315 | $148K |
| 93970 | <1% | 1,265 | $148K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,662 | $146K |
| Z9725 | <1% | 3,268 | $141K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,570 | $140K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,394 | $128K |
| 83880 | <1% | 6,780 | $128K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 711 | $125K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 805 | $120K |
| 87634 | <1% | 3,344 | $119K | |
| 93975 | <1% | 725 | $116K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,458 | $114K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 513 | $110K |
| 0259 | <1% | 4,458 | $103K | |
| 80076 | <1% | 13,799 | $98K | |
| 81001 | <1% | 28,147 | $93K | |
| 83690 | <1% | 15,372 | $86K | |
| 0762 | <1% | 1,906 | $82K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,739 | $81K |
| 70486 | <1% | 704 | $74K | |
| 82805 | <1% | 1,710 | $72K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,486 | $64K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,366 | $62K |
| 0121 | <1% | 28 | $61K | |
| 85610 | <1% | 13,149 | $60K | |
| 83605 | <1% | 5,370 | $59K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,442 | $59K |
| 0710 | <1% | 2,639 | $57K | |
| 86850 | <1% | 4,341 | $57K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,211 | $57K |
| 85730 | <1% | 8,747 | $55K | |
| 87040 | <1% | 2,981 | $54K | |
| 72131 | <1% | 516 | $50K | |
| 84702 | <1% | 4,123 | $49K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,284 | $48K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,710 | $46K |
| 73564 | <1% | 1,921 | $45K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,889 | $44K |
| Z7610 | <1% | 4,872 | $44K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,121 | $42K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 452 | $41K |
| 87088 | <1% | 3,539 | $41K | |
| 73130 | <1% | 1,789 | $41K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,195 | $40K |
| 82077 | <1% | 4,229 | $40K | |
| 76801 | <1% | 987 | $38K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,148 | $37K |
| 73610 | <1% | 1,765 | $36K | |
| 83735 | <1% | 6,868 | $35K | |
| 73030 | <1% | 1,642 | $34K | |
| 0214 | <1% | 44 | $33K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,265 | $32K |
| 59025 | Fetal non-stress test | <1% | 2,606 | $32K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,361 | $30K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 708 | $29K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,501 | $28K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,125 | $28K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,449 | $28K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 479 | $27K |
| 36000 | <1% | 2,029 | $27K | |
| 80299 | <1% | 2,274 | $27K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,481 | $26K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 689 | $25K |
| 0251 | <1% | 823 | $25K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,591 | $25K |
| 93971 | <1% | 373 | $25K | |
| 73630 | <1% | 1,457 | $25K | |
| 87186 | <1% | 3,154 | $24K | |
| 80179 | <1% | 2,255 | $24K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 327 | $24K |
| 82330 | <1% | 1,389 | $23K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 567 | $21K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,321 | $20K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,081 | $20K |
| 90715 | <1% | 698 | $20K | |
| 81003 | <1% | 4,087 | $17K | |
| 86900 | <1% | 4,755 | $17K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 772 | $16K |
| 96376 | <1% | 1,416 | $15K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,985 | $15K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 91 | $15K |
| 86901 | <1% | 4,705 | $15K | |
| 0300 | <1% | 1,126 | $14K | |
| 76802 | <1% | 560 | $13K | |
| 73110 | <1% | 620 | $13K | |
| 73590 | <1% | 686 | $11K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,793 | $11K |
| 72100 | <1% | 497 | $11K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,147 | $11K |
| 0320 | <1% | 295 | $10K | |
| 0252 | <1% | 446 | $10K | |
| 87077 | <1% | 978 | $10K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,160 | $9K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,548 | $9K |
| 70496 | <1% | 44 | $9K | |
| 82948 | <1% | 2,279 | $8K | |
| 82550 | <1% | 1,393 | $8K | |
| 0370 | <1% | 274 | $7K | |
| 87905 | <1% | 894 | $7K | |
| 71250 | <1% | 81 | $7K | |
| 73080 | <1% | 350 | $7K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 107 | $7K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 246 | $6K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 54 | $6K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,786 | $6K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,696 | $6K |
| 84132 | <1% | 947 | $6K | |
| 0301 | <1% | 481 | $6K | |
| 87808 | <1% | 880 | $6K | |
| 84295 | <1% | 828 | $6K | |
| 92650 | <1% | 482 | $5K | |
| 87210 | <1% | 903 | $5K | |
| 82947 | <1% | 383 | $5K | |
| 0258 | <1% | 536 | $5K | |
| 80061 | Lipid panel | <1% | 1,186 | $5K |
| 84439 | <1% | 634 | $5K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 656 | $5K |
| 82435 | <1% | 825 | $5K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,456 | $5K |
| 85018 | <1% | 1,133 | $5K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 988 | $5K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 870 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 994 | $5K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 78 | $5K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 500 | $4K |
| A4217 | Sterile water/saline, 500 ml | <1% | 801 | $4K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 708 | $4K |
| 87081 | <1% | 359 | $4K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 461 | $4K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 87 | $4K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 698 | $4K |
| 93293 | <1% | 136 | $4K | |
| 73502 | <1% | 159 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 390 | $4K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 79 | $4K |
| 83615 | <1% | 904 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 503 | $3K |
| 85379 | <1% | 455 | $3K | |
| 85380 | <1% | 729 | $3K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 357 | $3K |
| 73090 | <1% | 206 | $3K | |
| Z9726 | <1% | 66 | $3K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 288 | $3K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 38 | $3K |
| 82150 | <1% | 665 | $3K | |
| 96367 | <1% | 81 | $2K | |
| 81025 | <1% | 617 | $2K | |
| 76870 | <1% | 58 | $2K | |
| 36600 | <1% | 364 | $2K | |
| 87430 | <1% | 220 | $2K | |
| 72040 | <1% | 119 | $2K | |
| 84100 | <1% | 1,326 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 268 | $2K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 53 | $2K |
| 73100 | <1% | 127 | $2K | |
| 73560 | <1% | 41 | $2K | |
| 86140 | <1% | 338 | $2K | |
| 73562 | <1% | 92 | $2K | |
| 97161 | <1% | 72 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 389 | $1K |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 119 | $1K |
| 0160 | <1% | 20 | $1K | |
| 70498 | <1% | 15 | $992.96 | |
| 87150 | <1% | 24 | $991.15 | |
| J1980 | Injection, hyoscyamine sulfate, up to 0.25 mg | <1% | 160 | $975.77 |
| A9270 | Non-covered item or service | <1% | 876 | $961.77 |
| 73620 | <1% | 69 | $933.51 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 123 | $928.30 |
| J1741 | Injection, ibuprofen, 100 mg | <1% | 119 | $829.60 |
| 71010 | <1% | 60 | $814.44 | |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | <1% | 43 | $767.53 |
| 82248 | <1% | 170 | $741.48 | |
| 87581 | <1% | 35 | $704.84 | |
| Z7514 | <1% | 12 | $701.64 | |
| 87497 | <1% | 860 | $696.40 | |
| 82140 | <1% | 60 | $689.44 | |
| 87486 | <1% | 35 | $673.65 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 99 | $648.96 |
| 73070 | <1% | 40 | $610.73 | |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | <1% | 50 | $592.99 |
| 74018 | <1% | 48 | $567.86 | |
| A4649 | Surgical supply; miscellaneous | <1% | 4,062 | $539.19 |
| 87147 | <1% | 173 | $483.10 | |
| 99000 | <1% | 190 | $477.57 | |
| J1815 | Injection, insulin, per 5 units | <1% | 117 | $473.45 |
| 71101 | <1% | 33 | $444.27 | |
| 93280 | <1% | 13 | $435.33 | |
| 87799 | <1% | 360 | $426.67 | |
| 86780 | <1% | 58 | $397.99 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 33 | $360.95 |
| 86920 | <1% | 15 | $324.92 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 64 | $303.97 |
| 80197 | <1% | 950 | $267.64 | |
| 71100 | <1% | 17 | $253.20 | |
| 85027 | <1% | 84 | $243.57 | |
| 72072 | <1% | 14 | $238.81 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 16 | $188.24 |
| 82570 | <1% | 490 | $183.27 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 35 | $181.54 |
| 86332 | <1% | 489 | $177.76 | |
| 84550 | <1% | 119 | $176.07 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 15 | $174.77 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 23 | $174.45 |
| 0294 | <1% | 102 | $138.61 | |
| 73140 | <1% | 13 | $133.28 | |
| 87807 | <1% | 30 | $129.93 | |
| 85651 | <1% | 153 | $121.41 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 27 | $120.95 |
| 12002 | <1% | 13 | $120.00 | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $104.50 |
| 82553 | <1% | 12 | $101.95 | |
| 0420 | <1% | 16 | $99.94 | |
| 0350 | <1% | 40 | $96.91 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 14 | $87.06 |
| 84156 | <1% | 452 | $80.08 | |
| 51701 | <1% | 13 | $80.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 21 | $74.14 |
| 80305 | <1% | 12 | $71.82 | |
| 0306 | <1% | 311 | $70.86 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 14 | $70.55 |
| 87070 | <1% | 14 | $39.33 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 147 | $25.65 |
| 0272 | <1% | 111 | $23.71 | |
| 0636 | <1% | 269 | $22.82 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 15 | $20.12 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 15 | $18.39 |
| 0305 | <1% | 445 | $16.54 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 43 | $6.63 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 29 | $4.95 |
| 0310 | 0% | 162 | $0.00 | |
| 0307 | 0% | 88 | $0.00 | |
| A4300 | Implantable access catheter, (e.g., venous, arterial, epidural subarachnoid, or peritoneal, etc.) external access | 0% | 381 | $0.00 |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 14 | $0.00 |
| 0730 | 0% | 174 | $0.00 | |
| 0510 | 0% | 37 | $0.00 | |
| 0302 | 0% | 64 | $0.00 | |
| V2630 | Anterior chamber intraocular lens | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPONCE (AKA CARLSON), SUSANNE (SUE) (SPECIAL PROJECTS)